PRTK - Paratek Pharmaceuticals GAAP EPS of -$0.35 in-line revenue of $24.86M misses by $2.29M
Paratek Pharmaceuticals press release (NASDAQ:PRTK): Q1 GAAP EPS of -$0.35 in-line. Revenue of $24.86M (+51.3% Y/Y) misses by $2.29M. Anticipates its existing cash, cash equivalents and marketable securities of $79.1 million as of March 31, 2022, provides for a cash runway through the end of 2023 with a pathway to cash flow break-even.
For further details see:
Paratek Pharmaceuticals GAAP EPS of -$0.35 in-line, revenue of $24.86M misses by $2.29M